Robert Wesolowski
Overview
Explore the profile of Robert Wesolowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
1919
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chowdhury S, Hong F, Rolfo C, Li Z, He K, Wesolowski R, et al.
Biology (Basel)
. 2025 Feb;
14(2).
PMID: 40001982
Canopy FGF signaling regulator 2 (CNPY2) has emerged as a crucial player in cancer development by promoting cell proliferation, tissue repair, and angiogenesis. This review synthesizes the current understanding of...
2.
Prasath V, Boutrid H, Wesolowski R, Abdel-Rasoul M, Timmers C, Lustberg M, et al.
Breast Cancer Res Treat
. 2024 Dec;
210(1):179-189.
PMID: 39644403
Purpose: While MEK inhibitors demonstrated activity in metastatic triple negative breast cancer (mTNBC) preclinical studies, preclinical, and clinical studies implicate rapid development of resistance limiting clinical benefit. The purpose of...
3.
Otto-Dobos L, Strehle L, Loman B, Seng M, Sardesai S, Williams N, et al.
NPJ Breast Cancer
. 2024 Nov;
10(1):99.
PMID: 39548124
Chemotherapy frequently causes debilitating gastrointestinal symptoms, which are inadequately managed by current treatments. Recent research indicates the gut microbiome plays a role in the pathogenesis of these symptoms. The current...
4.
Schwarz E, Benner B, Wesolowski R, Quiroga D, Good L, Sun S, et al.
JCI Insight
. 2024 Nov;
9(21).
PMID: 39513363
BACKGROUNDInhibition of Bruton's tyrosine kinase with ibrutinib blocks the function of myeloid-derived suppressor cells (MDSC). The combination of ibrutinib and nivolumab was tested in patients with metastatic solid tumors.METHODSSixteen patients...
5.
Manouchehri J, Datta J, Marcho L, Reardon J, Stover D, Wesolowski R, et al.
Breast Cancer Res
. 2024 Nov;
26(1):153.
PMID: 39506780
Background: Breast cancer, one of the most common forms of cancer, is associated with the highest cancer-related mortality among women worldwide. In comparison to other types of breast cancer, patients...
6.
Su Z, Guo Y, Wesolowski R, Tozbikian G, OConnell N, Khan Niazi M, et al.
ArXiv
. 2024 Oct;
PMID: 39398198
Accurate recurrence risk stratification is crucial for optimizing treatment plans for breast cancer patients. Current prognostic tools like Oncotype DX (ODX) offer valuable genomic insights for HR+/HER2- patients but are...
7.
Rixe O, Villano J, Wesolowski R, Noonan A, Puduvalli V, Wise-Draper T, et al.
Clin Cancer Res
. 2024 Sep;
30(22):5053-5060.
PMID: 39264252
Purpose: BXQ-350, a nanovesicle formulation of saposin C, is an allosteric sphingolipid metabolism regulator that increases proapoptotic ceramide and decreases oncogenic sphingosine-1-phosphate levels. We conducted a first-in-human phase I study...
8.
Rezapour M, Wesolowski R, Gurcan M
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000413
Our study aims to address the methodological challenges frequently encountered in RNA-Seq data analysis within cancer studies. Specifically, it enhances the identification of key genes involved in axillary lymph node...
9.
Johnson K, Ni A, Quiroga D, Pariser A, Sudheendra P, Williams N, et al.
NPJ Breast Cancer
. 2024 Jun;
10(1):49.
PMID: 38898072
There is limited data regarding the added benefit of adjuvant systemic therapy in the management of small, node-negative, HER2+ breast cancer. In a multi-institutional retrospective analysis using the American Society...
10.
Sukumar J, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, et al.
Cancer Med
. 2024 Jun;
13(12):e7317.
PMID: 38895891
Background: The optimal adjuvant endocrine therapy (ET) in hormone receptor positive (HR+) and human epidermal growth factor receptor 2 positive (HER2+) premenopausal breast cancer (BC) remains unclear. Moreover, the benefit...